Targets, Tracers and Translation - Novel Radiopharmaceuticals Boost Nuclear Medicine
This is the fourth Special Issue in Pharmaceuticals within the last six years dealing with aspects of radiopharmaceutical sciences. It demonstrates the significant interest and increasing relevance to ameliorate nuclear medicine imaging with PET or SPECT, and also radiotherapeutical procedures.Numer...
| Format: | eBook |
|---|---|
| Language: | English |
| Published: |
MDPI - Multidisciplinary Digital Publishing Institute
2019
|
| Subjects: | |
| Online Access: | Open Access: DOAB: description of the publication Open Access: DOAB, download the publication |
| LEADER | 04604namaa2201321uu 4500 | ||
|---|---|---|---|
| 001 | doab60492 | ||
| 003 | oapen | ||
| 005 | 20210212 | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 210212s2019 xx |||||o ||| 0|eng d | ||
| 020 | |a 9783039213139 | ||
| 020 | |a 9783039213146 | ||
| 020 | |a books978-3-03921-314-6 | ||
| 024 | 7 | |a 10.3390/books978-3-03921-314-6 |2 doi | |
| 040 | |a oapen |c oapen | ||
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a M |2 bicssc | |
| 720 | 1 | |a Reischl, Gerald |4 aut | |
| 245 | 0 | 0 | |a Targets, Tracers and Translation - Novel Radiopharmaceuticals Boost Nuclear Medicine |
| 260 | |b MDPI - Multidisciplinary Digital Publishing Institute |c 2019 | ||
| 300 | |a 1 online resource (214 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |f Unrestricted online access |2 star | |
| 520 | |a This is the fourth Special Issue in Pharmaceuticals within the last six years dealing with aspects of radiopharmaceutical sciences. It demonstrates the significant interest and increasing relevance to ameliorate nuclear medicine imaging with PET or SPECT, and also radiotherapeutical procedures.Numerous targets and mechanisms have been identified and have been under investigation over the previous years, covering many fields of medical and clinical research. This development is well illustrated by the articles in the present issue, including 13 original research papers and one review, covering a broad range of actual research topics in the field of radiopharmaceutical sciences. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by-nc-nd/4.0/ |2 cc |u https://creativecommons.org/licenses/by-nc-nd/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 653 | |a ?-CIT. | ||
| 653 | |a [11C]meta-hydroxyephedrine | ||
| 653 | |a [18F]FMISO | ||
| 653 | |a [18F]PSS232 | ||
| 653 | |a 177Lu-radiopharmaceuticals | ||
| 653 | |a 4-dioxide (BTDO) | ||
| 653 | |a 68Ga | ||
| 653 | |a 99mTc-radioligand | ||
| 653 | |a 99mTc-radiopharmaceuticals | ||
| 653 | |a ABP688 | ||
| 653 | |a allosteric modulator | ||
| 653 | |a apparent molar activity | ||
| 653 | |a azomycin nucleosides | ||
| 653 | |a benzotriazine-1 | ||
| 653 | |a benzotriazine-1-monoxide (BTMO) | ||
| 653 | |a bombesin | ||
| 653 | |a breast cancer | ||
| 653 | |a carbon-11 | ||
| 653 | |a carbonic anhydrase IX | ||
| 653 | |a ceftriaxone | ||
| 653 | |a Chloramine T | ||
| 653 | |a cholecystokinin-2 receptor | ||
| 653 | |a click chemistry | ||
| 653 | |a dextran | ||
| 653 | |a electrophilic radioiodination | ||
| 653 | |a endoradiotherapy | ||
| 653 | |a Fusarinine C | ||
| 653 | |a gallium-68 | ||
| 653 | |a gastrin-releasing peptide | ||
| 653 | |a gastrin-releasing peptide receptor | ||
| 653 | |a girentuximab | ||
| 653 | |a glutamate | ||
| 653 | |a GRPR | ||
| 653 | |a hydrazinonicotinic acid (HYNIC) | ||
| 653 | |a hypoxia | ||
| 653 | |a iodine-131 | ||
| 653 | |a Iodo-Gen® | ||
| 653 | |a ketamine | ||
| 653 | |a mannose | ||
| 653 | |a metabolic stability | ||
| 653 | |a metabotropic glutamate receptor subtype 5 | ||
| 653 | |a microglia | ||
| 653 | |a minigastrin | ||
| 653 | |a MMPEP | ||
| 653 | |a molecular imaging | ||
| 653 | |a multimerization | ||
| 653 | |a n/a | ||
| 653 | |a neprilysin-inhibition | ||
| 653 | |a neurodegeneration | ||
| 653 | |a neuroinflammation | ||
| 653 | |a NPY(Y1)R | ||
| 653 | |a oncogenic fusions | ||
| 653 | |a oxidizing agent | ||
| 653 | |a peptide heterodimers | ||
| 653 | |a PET | ||
| 653 | |a PET/CT imaging | ||
| 653 | |a phosphoramidon | ||
| 653 | |a positron emission tomography | ||
| 653 | |a pretargeting | ||
| 653 | |a prostate cancer | ||
| 653 | |a PSMA-617 | ||
| 653 | |a radiochemistry | ||
| 653 | |a radioimmunotherapy | ||
| 653 | |a radioiodination | ||
| 653 | |a radiometals | ||
| 653 | |a radiosensitizer | ||
| 653 | |a radiosynthesis | ||
| 653 | |a renal cell carcinomas | ||
| 653 | |a rituximab | ||
| 653 | |a salivary gland uptake | ||
| 653 | |a sentinel lymph node | ||
| 653 | |a separation | ||
| 653 | |a small animal imaging | ||
| 653 | |a SR 4317 | ||
| 653 | |a technetium-99m | ||
| 653 | |a tirapazamine (TPZ) | ||
| 653 | |a tropomyosin receptor kinase | ||
| 653 | |a tumor hypoxia | ||
| 653 | |a tumor targeting | ||
| 793 | 0 | |a DOAB Library. | |
| 856 | 4 | 0 | |u https://directory.doabooks.org/handle/20.500.12854/60492 |7 0 |z Open Access: DOAB: description of the publication |
| 856 | 4 | 0 | |u https://mdpi.com/books/pdfview/book/1555 |7 0 |z Open Access: DOAB, download the publication |